CommercialPrior AuthMedium impact
08.02.35, Drugs, Biologics, or Gene Therapies with an Accelerated Approval
Independence Blue Cross·Pharmacy, Oncology, Internal Medicine·Pharmacy
Effective date
Nov 12, 2025
We identified it
Jun 19, 2026
Summary
This policy (08.02.35) addresses coverage and billing requirements for drugs, biologics, or gene therapies that have received FDA accelerated approval status. The reissue effective 11/12/2025 establishes guidelines for how these therapies are managed within the insurance plan. Billing teams must understand the prior authorization, coverage criteria, and documentation requirements for accelerated approval medications.
Action Required
By 11/12/2025: Billing and clinical teams must obtain and review the full policy text from the provided URL to identify specific prior authorization requirements, covered indications, and documentation standards for accelerated approval drugs, biologics, and gene therapies. Update prior authorization workflows and billing system rules to reflect any new requirements. Train providers and billing staff on submission requirements for these therapies. Failure to comply with prior authorization and coverage criteria will result in claim denials.